ImmunityBio signed an exclusive development and supply agreement with Japan BCG Laboratory (JBL) for the Tokyo-172 strain of BCG. The agreement grants ImmunityBio exclusive rights to import, sell, and distribute the product in the U.S. for 10 years post-FDA approval. ImmunityBio will act as the sole Biologics License Application (BLA) applicant and lead all regulatory and clinical development activities. The Tokyo-172 strain demonstrated non-inferiority to TICE BCG in the Phase III SWOG S1602 trial, with a hazard ratio of 0.82. No payments are due to JBL prior to FDA approval; post-approval, ImmunityBio commits to purchasing at least 2 batches annually.